February 24, 2022 7:37am

Volatility is beyond normal, as the 52-week lows are multiplying while Q4 and FY21 earnings don’t help share pricings

Pre-open indications:  8 SELL indications and 1 pimp/pump/promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Earnings Reporting (today): Sage Therapeutics (SAGE), Ionis Pharmaceuticals (IONS),  Sangamo Therapeutics (SGMO) and Editas Medicine (EDIT

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

Only the facts … I ask questions and note the indications

3Dow futures are DOWN -2.39% (-791 points), S&P futures are DOWN -2.44% (-103 points) and NASDAQ futures are DOWN -308% (-416 points)

 

U.S. stock futures plunged in the pre-open market on Thursday,

European markets sold -off abruptly after Russia launched an attack on Ukraine with the Stoxx 600 down -2.7%,

Asia-Pacific markets declined as oil futures jumped, rising 6.21% to trade at $97.82 per barrel in Asia. The international benchmark Brent crude futures climbed by 6.54% to $103.17 per barrel, crossing the $100 level for the first time since 2014.

 

Henry’omics:

The pressured, anxious and tense stock market tried to bounce Wednesday, but then sold off hard, with the Dow Jones, S&P 500 and Nasdaq undercutting their Jan. 24 lows.

  • As the Dow dropped about 464 points, or 1.3%, The S&P 500 fell 1.8%, moving deeper into correction and ending the day about 12% from its Jan. 3 record close with the Nasdaq losing 2.6%.
  • Moscow suspended trading on all markets. The ruble tumbled to lows vs. major currencies in overseas trading.

Oil prices popped as fighting commenced, with West Texas Intermediate futures trading 7.2% higher at just shy of $100 per barrel.

  • Global benchmark Brent jumped 7.7% to $104.56 per barrel, passing the $100 level for the first time since 2014.
  •  Also, treasury yields tumbled, with the benchmark 10-year note declining to 1.86% as investors sought safe-haven bonds. <CNBC>

 

Economic Data Docket: GDP and jobless claims before the opening bell and new home sales figures.

 

RegMed Investors’ (RMi) closing bell: “what happened, blood from the past and on-going sessions drowns sentiment. Another free fall with declining sector equities, just when one thought a partial clear signal could have been issued” … https://www.regmedinvestors.com/articles/12313

Ebb and flow –

  • February stats: 11 negative and 5 positive closes
  • January stats: 1 holiday, 1 neutral, 13 negative and 6 positive closes

 

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ... Global Blood Therapeutics (GBT) added

 

The Biostage (OTC: QB: BSTG) Chronicles: Who, What, When, Where, Why and one H (HOW) … https://www.regmedinvestors.com/articles/12306

 

Companies in my headlights – It’s your decision; I provide ideas and context:

SELL on indication:

  • Fate Therapeutics (FATE- $1.31) -$0.58 or -1.822% <reports Q4/FY21 next Monday
  • Sage Therapeutics (SAGE -$1.43) -$0.61 or -1.87% <reports earnings today >
  • Ionis Pharmaceuticals (IONS -$0.61) $0.00
  • Alnylam Pharmaceuticals (ALNY +$0.66) -$2.47 or -1.67%
  • Editas Medicine (EDIT -$0.60) -$0.19 or -1.32% < reports earnings today >
  • Sangamo Therapeutics (SGMO -$0.36) -0.06 or -1.12% <reports earnings today >
  • CRISPR Therapeutics (CRSP -$2.41) -$2.45 or -4.60%
  • ReNeuron (RENE.L +$1.50) -$2.50 or -7.25%
  • UniQure NV (QURE -$0.31) -1.20 or -7.46%

 

Pimp/Pump and Promote:

Biostage (OTCQB: BSTG) closed up +$0.20 on Wednesday with an “out-of-the air” block of 3,070 after Tuesday’s +$0.62 with 4,225 shares out-of-nowhere after Friday’s -$0.68 to $3.88 with 103 trading shares traded after Thursday’s +$0.06 with 700 shares traded after Wednesday -$0.06 (had been -$0.98) with 420 shares traded, Tuesday’s flat with 200 shares traded and Monday’s flat with 1,899 shares traded

  • WHO is BUYING these shares of a company with a 2-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
  • Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering - they’re NOT going ANYWHERE without a cash inflow.

 

The BOTTOM LINE: Flak jackets, knee pads and boots to wade in the share pricing carnage, night/thermal vision needed – to see what’s coming at us … as the tanks have rolled, a “fait accompli” now let’s watch and wait on any upside to diminish and the grossly oversold burn.

To add to the chaos and uncertainty, this week has “heavy” earnings reporting

Earnings’ reporting:

·         Sage Therapeutics (SAGE), Thursday, 2/24

·         Ionis Pharmaceuticals (IONS) - Thursday, 2/24

·         Sangamo Therapeutics (SGMO) - Thursday, 2/24

·         Editas Medicine (EDIT) - Thursday, 2/24

·         Fate Therapeutics, Monday, 2/28

·         BioLife Solutions (BLFS), Monday,2/28

·         Athersys (ATHX), Tuesday, 3/15

Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in FATE, CRS, securities referred to in this publication.